|  |  |
| --- | --- |
| **Supplementary Table 2.**  Clinical characteristics of the diffuse pulmonary 131I accumulation group (n = 11) | |
| Age (years) | 47 ± 25 (range: 13 to 81) |
| Sex, Male | 8 |
| Days from surgery to the initial RAI | 1398 [164, 4212] |
| 131I-avid accumulation |  |
| Average countof 131I-avid area | 0.53 [0.29, 0.84] |
| Lung metastases |  |
| Undetectable | 1 |
| ≤10 mm | 8 |
| >10 mm | 2 |
| Bone metastases | 0 |
| The primary thyroid tumor |  |
| Histological classification |  |
| Follicular carcinoma | 2 |
| Papillary carcinoma | 8 |
| Follicular carcinoma and papillary carcinoma | 0 |
| Poorly differentiated carcinoma | 0 |
| Unknown | 1 |
| T classification |  |
| T1 | 0 |
| T2 | 0 |
| T3 | 3 |
| T4 | 5 |
| TX | 3 |
| The preoperative 18F-FDG PET-CT SUVmax of the primary thyroid tumor (n = 3) | 3.4 ± 2.1 |
| The serum Tg (ng/mL) | 428 [168, 1484] |
| The serum TgAb (IU/mL) |  |
| <10.0 | 9 |
| 400.0< | 2 |
| RAI treatment only | 9 |
| Total number of RAI |  |
| 1 | 0 |
| 2 | 1 |
| 3 | 4 |
| 4 | 2 |
| ≥5 | 4 |
| Cumulative activity of 131I (MBq) | 12950 [9250, 16450] |
| Surgical resection for metastasis following initial RAI | 1 |
| Molecular targeted therapy | 1 |
| Radiation therapy | 0 |
| Data are n, mean ± SD or median [IQR]. RAI, radioactive iodine; SUVmax, maximum standardized uptake value; Tg, thyroglobulin; TgAb, anti-thyroglobulin antibodies. The serum Tg and TgAb were measured at the time of initial RAI therapy, Levothyroxine withdrawal. | |